Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700582 | 0.85 | NR3C2 (0.47) | NR3C2BCAT2ESR1ESR2HPGD | |
| SCHEMBL8377361 | 0.68 | MAPK1 (0.41) | BCAT2HPGDALDH1A1METAP2 | |
| SCHEMBL9067488 | 0.67 | ESR1 (0.76) | NR3C2ESR1ESR2HPGDNPSR1 | |
| SCHEMBL701755 | 0.67 | ESR1 (0.45) | NR3C2ESR1ESR2NPSR1ALDH1A1 | |
| SCHEMBL1780547 | 0.66 | ALDH1A1 (0.35) | BCAT2ALDH1A1 | |
| SCHEMBL9001692 | 0.65 | NPSR1 (0.61) | NR3C2ESR1ESR2HPGDNPSR1 | |
| SCHEMBL28316178 | 0.65 | ESR1 (0.54) | NR3C2BCAT2ESR1ESR2HPGD | |
| SCHEMBL15999739 | 0.65 | ESR1 (0.57) | ESR1ESR2HPGDNPSR1ALDH1A1 | |
| SCHEMBL1878316 | 0.62 | MEN1 (0.42) | BCAT2ALDH1A1 | |
| SCHEMBL15290442 | 0.62 | ESR1 (0.91) | NR3C2ESR1ESR2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124810-B2 | Preparation of isoxazolin-3-ylacylbenzenes | BASF SE (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8049017-B2 | Preparation of isoxazolin-3-ylacylbenzenes | BASF SE (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110152535-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | RHEINHEIMER JOACHIM | 2011-06-23 | — | — | US | disclosed |
| US-20100105920-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | BASF SE (DE) | 2010-04-29 | — | — | US | disclosed |
| US-7663001-B2 | Preparation of isoxazolin-3-ylacylbenzene | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7309802-B2 | Preparation of isoxazolin-3-ylacylbenzene | BASF AKTIENGESELLSCHAFT (DE) | 2007-12-18 | — | — | US | disclosed |
| US-20070161800-A1 | Preparation of Isoxazolin-3-Ylacylbenzene | BASF SE (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20030216580-A1 | Preparation of Isoxazolin-3-Ylacylbenzene | BASF SE (DE) | 2003-11-20 | — | — | US | disclosed |
| US-6608209-B2 | Reacting a nitro-o-methylphenyl compound with an organic nitrite in presence of a base to give an oxime, cyclizing the oxime with an alkene in presence of a base to give an intermediate, reducing nitrogroup in presence of catalyst | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-19 | — | — | US | disclosed |
| US-6525204-B1 | Oximination reaction of nitro-o-methylphenyl compound with organic nitrite; cyclization with alkene in basic catalyst presence; reduction, bromination, oxidation, carboxylation | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| US-20030018200-A1 | Preparation of isoxazolin-3-ylacylbenzenes | BASF SE (DE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161800-A1 | Preparation of Isoxazolin-3-Ylacylbenzene | CBR3, UQCRB, CYP4X1 | NR3C2 2011/4885BCAT2 767/4885ESR1 3424/4885 |
| US-20110152535-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | CBR3, CYP4X1, UQCRB | NR3C2 1930/4885BCAT2 884/4885ESR1 3245/4885 |
| US-20100105920-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | CBR3, CYP4X1, UQCRB | NR3C2 1930/4885BCAT2 884/4885ESR1 3245/4885 |
| US-20030216580-A1 | Preparation of Isoxazolin-3-Ylacylbenzene | UQCRB, CYP1B1, CYP2F1 | NR3C2 1712/4885BCAT2 669/4885ESR1 4158/4885 |
| US-20030018200-A1 | Preparation of isoxazolin-3-ylacylbenzenes | CYP2F1, UQCRB, CYP1B1 | NR3C2 1453/4885BCAT2 818/4885ESR1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.